PolyPid Ltd. (PYPD) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the PolyPid second quarter 2026 conference call. As a reminder, this call is recorded and I would now like to introduce your host for today's conference, Yuda Liebler from ARCS Investor Relations. Mr. Liebler, you may begin. Thank you, operator, and thank you all for joining PolyPid's second quarter 2026 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid, Jonny Missulawin, PolyPid's Chief Financial Officer, and Ori Warshavsky, Chief Operating Officer, U.S., of PolyPid. Earlier today, PolyPid released its financial results for the three and six months ended June 30, 2026. A copy of the press release is available on the Investors section of the company's website at www.polypid.com. I'd like to remind you all that on this call, management will make forward-looking statements within the meaning of the federal securities laws. For example, management is making forward-looking statements when it's discussing the company's exclusive commercialization partnership with Azordi Pharmaceuticals for the United States and Canada. These forward-looking statements include the partnership's economic structure, including the potential milestone payments, tiered royalties, and transfer price, the joint development activities and label expansion program contemplated under the agreement, the expected timing and progress towards potential U.S. Food and Drug Administration or FDA approval of DPLEX-100 including the assigned Prescription Drug User Fee Act or PDUFA goal date and the FDA's grant of priority review. Additional forward-looking statements include the company's engagements with the European Medicines Agency including meetings with the repertoire and co-repertoire regarding the planne...